

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human USP8 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human USP2 is observed.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	<i>E. coli</i> -derived recombinant human USP8 Met1-Thr1118 Accession # P40818
Conjugate	Alexa Fluor 700 Excitation Wavelength: 675-700 nm Emission Wavelength: 723 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

USP8 (Ubiquitin-Specific-Processing protein 8; also UBPY and ubiquitin carboxyterminal hydrolase 8) is a 125-130 kDa member of the peptidase C19 family of proteins. It is a widely expressed deubiquitinating enzyme that regulates the internalization and trafficking of transmembrane growth factor receptors. Ubiquitinated TKRs are typically targeted for internalization and degradation, and USP8 appears to block this activity. Conversely, USP8 has been shown to have opposite effects on GPCR activity. Here, it accelerates ubiquitinated chemokine receptor (CXCR4) internalization and subsequent inactivation, notably through a deubiquitination-independent mechanism. Human USP8 is 1118 amino acids (aa) in length. It contains one MIT domain that mediates endosomal trafficking (aa 33-116), a rhodanese domain that binds RNF proteins (aa 184-305), an SH3 domain binding sequence (aa 405-413), and a C-terminal catalytic domain that hydrolyses ubiquitin adducts (aa 776-1106). USP8 is phosphorylated at Ser702, 705, 784 and 787. There is one oncogenic recombination isoform that fuses the p85 β-subunit of PI3 kinase to the C-terminal 363 aa of USP8, beginning with Pro746. Full-length human and mouse USP8 share 82% aa sequence identity.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.